Oxford Finance LLC is a specialty finance firm that provides senior debt financing, including term loans and working capital lines of credit, to public and private life sciences and healthcare services companies. The company focuses on businesses in various stages of development, from early-stage to commercial-stage companies.

Oxford Finance LLC, headquartered in Alexandria, Virginia, is a specialty financial services firm that provides capital for growth and development to life sciences and healthcare services companies worldwide. For over two decades, our management team has been delivering loans to some of the most innovative participants in this industry.

Oxford has remained a leader in the lending industry because of our commitment to remain fair, flexible and responsive to the changing needs of our clients. Over the past few years, we have originated over $8.5 billion in loans to over 500 companies, with credit facilities ranging from $5 million to $200 million.

4D Pharma

Centogene

Kala Pharmaceuticals

CVRx

CymaBay Therapeutics

Amicus Therapeutics

CareDx

Xeris Pharmaceuticals

Zogenix

NanoString Technologies

Equillium

SpendMend

Greenbrook

Asensus Surgical

Verastem Oncology

RxSight

Senseonics

Sierra Oncology

Pulmonx

Reata Pharmaceuticals

Codex DNA

ReShape Lifesciences

Horizon Pharma

HTG Molecular Diagnostics

Immunocore

Impel NeuroPharma

Oxford Finance LLC

Oxford Finance is pleased to sponsor the upcoming eCap West Summit. We look forward to meeting you there to talk about financing for your transaction. Please reach out to Kevin Harbour or Richard Russakoff to connect with us.

Oxford’s Life Sciences Team is thrilled to announce the expansion of our relationship with long-time client, Pliant Therapeutics, a clinical-stage biopharmaceutical company leading the way in developing new treatments for fibrotic diseases. The facility will support the continued clinical development of PLN-74809, an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 for the treatment of idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

View Full Press Release: https://shorturl.at/bvzO8

Oxford’s Life Sciences Team recently expanded our relationship with long-time client, Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs.

“We are thrilled to announce our expanded financial support for our existing client, Verona Pharma,” said Adam K. Soller, Managing Director at Oxford. “As we anticipate their first potential approval of the company’s lead product candidate, ensifentrine, for the maintenance treatment of patients with COPD, our increased loan facility underscores our commitment to advancing ground-breaking solutions for respiratory health.”

https://lnkd.in/e83FSmH5

Oxford Finance is pleased to sponsor the upcoming eCap Summit. We look forward to meeting you there to talk about financing for your transaction. Please reach out to Kevin Harbour, Matthew Pulley or Richard Russakoff to connect with us.

Oxford Finance will be attending HLTH 2023 in Las Vegas from October 8-11. If you are planning to attend, please reach out directly to one of our team members to connect - Christopher Herr, Adam Soller, David Hickman, Rohit Gandhi, Katherine Thornett 

#HLTH2023 #venturedebt #growthequity #lifesciences #leveragedfinance 

COM:OXFORDFINANCE

Oxford Finance LLC

Analysis Not Available